# **PRODUCT** INFORMATION



## **TAS 6417**

Item No. 27911

| CAS Registry No.: | 1661854-97-2                      |                 |
|-------------------|-----------------------------------|-----------------|
| Formal Name:      | N-[(8S)-4-amino-8,9-dihydro-      |                 |
|                   | 6-methyl-5-(3-quinolinyl)         |                 |
|                   | pyrimido[5,4-b]indolizin-8-yl]-2- |                 |
|                   | propenamide                       | NH <sub>2</sub> |
| Synonyms:         | CLN-081, Zipalertinib             |                 |
| MF:               | $C_{23}H_{20}N_{6}O$              |                 |
| FW:               | 396.4                             |                 |
| Purity:           | ≥98%                              |                 |
| Supplied as:      | A solid                           | O N             |
| Storage:          | -20°C                             | Н               |
| Stability:        | ≥4 years                          |                 |
|                   |                                   |                 |

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

#### Laboratory Procedures

TAS 6417 is supplied as a solid. A stock solution may be made by dissolving the TAS 6417 in the solvent of choice, which should be purged with an inert gas. TAS 6417 is soluble in acetonitrile and DMSO.

#### Description

TAS 6417 is a pan-EGFR inhibitor.<sup>1</sup> It inhibits wild-type EGFR (IC<sub>50</sub> = 8 nM), as well as the EGFR point mutants EGFR<sup>L858R</sup>, EGFR<sup>L861Q</sup>, EGFR<sup>T790M</sup>, EGFR<sup>T790M/L858R</sup> (IC<sub>50</sub>s = 1.9, 5.5, 4.1, and 2 nM, respectively) and the insertion or deletion mutants EGFR D770\_N771insNPG, EGFR d746-750, and EGFR d746-770/T790M (IC<sub>50</sub>s = 7.4, 1.4, and 1.1 nM, respectively). It is selective for these kinases over a panel of 20 additional kinases (IC<sub>50</sub>s = 44-850 nM) but does inhibit TXK, BMX, HER4, Tec, and BTK(IC<sub>50</sub>s = 1.1-22 nM). TAS 6417 inhibits the proliferation of LXF 2478L, H1975, HCC827, and PC-9 lung cancer cells (GI<sub>50</sub>s = 86.5, 45.4, 1.92, and 2.96 nM, respectively). In vivo, TAS 6417 (50, 100, and 200 mg/kg) reduces tumor volume and increases survival in an H1975 EGFR D770-N771insSVD mouse

#### Reference

1. Hasako, S., Terasaka, M., Abe, N., et al. TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations. Mol. Cancer Ther. 17(8), 1648-1658 (2018).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/13/2024

### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM